Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILOR-400 vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular c AMP and c GMP, resulting in bronchodilation and vasodilation.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
FDA-approved: Symptomatic management of chronic obstructive pulmonary disease (COPD) and other bronchospastic disorders.,Off-label: Treatment of bronchial asthma, pulmonary hypertension, and as an adjunct in heart failure.
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Hepatic metabolism via CYP1A2, CYP3A4, and CYP2E1; undergoes N-demethylation and oxidation to inactive metabolites.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal (70% unchanged), hepatic metabolism (30%)
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
40% bound, primarily to albumin
65% bound to albumin
0.5 L/kg (approximates total body water; indicates distribution into extracellular fluid)
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral: 95-100% (well absorbed from gastrointestinal tract)
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
GFR 10-50 m L/min: 400 mg every 8-12 hours; GFR <10 m L/min: 400 mg every 12-24 hours.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 400 mg every 8-12 hours; Child-Pugh Class C: 400 mg every 12-24 hours.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
6 months to 2 years: 8-12 mg/kg/day divided every 6 hours; 2-12 years: 12-16 mg/kg/day divided every 6 hours; maximum 600 mg/day.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Start at lower end of dosing range (400 mg every 8 hours) and titrate based on renal function and tolerability.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
None.
No FDA black box warning.
Cardiovascular: May cause hypotension, tachycardia, or arrhythmias; use with caution in patients with cardiovascular disease.,CNS: May cause insomnia, anxiety, or seizures; adjust dose in elderly or with hepatic impairment.,Renal: Excreted largely unchanged; caution in renal impairment.,Drug interactions: Increased toxicity with cimetidine, ciprofloxacin, and others that inhibit CYP1A2.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to dyphylline or any xanthine derivative.,Acute myocardial infarction.,Hypotension.,Uncontrolled arrhythmias.
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid high-caffeine foods (coffee, tea, cola, chocolate) as they increase risk of side effects. Charcoal-broiled foods may decrease drug absorption. High-fat meals may delay absorption; take on an empty stomach for consistent effect.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Teratogenic potential: Pregnancy Category C. First trimester: Limited human data, animal studies show fetal toxicity at high doses. Second and third trimesters: Potential for transient neonatal hypoglycemia, tachycardia, and irritability due to maternal xanthine exposure. Avoid use unless benefit outweighs risk.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Diphylline (active ingredient) is excreted into breast milk. M/P ratio not established. Potential for irritability and sleep disturbance in infants. Caution advised; consider alternative therapies.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
No well-established pharmacokinetic studies in pregnancy. However, plasma clearance of xanthines may decrease in late pregnancy due to reduced hepatic metabolism. Consider monitoring drug levels and adjusting dose to maintain therapeutic range. Initiate at lower end of dosing, titrate based on response and toxicity.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
DILOR-400 (diprophylline) is a xanthine bronchodilator with similar efficacy to theophylline but with reduced central nervous system stimulation. Monitor serum levels for therapeutic range (10-20 mcg/m L). Caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders. Adjust dose in hepatic impairment and elderly. Avoid concurrent use with other xanthines.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take exactly as prescribed; do not exceed recommended dose.,Do not crush or chew extended-release tablets.,Report nausea, vomiting, palpitations, or seizures immediately.,Avoid caffeine-containing foods and beverages.,Do not smoke or stop smoking without consulting doctor as dose may need adjustment.,Keep a regular dosing schedule; do not double up missed doses.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILOR-400 vs AEROLATE, answered by our medical review team.
DILOR-400 is a Bronchodilator that works by Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular c AMP and c GMP, resulting in bronchodilation and vasodilation.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILOR-400 and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILOR-400 is: 400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILOR-400 and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILOR-400 is classified as Category C. Teratogenic potential: Pregnancy Category C. First trimester: Limited human data, animal studies show fetal toxicity at high doses. Second and third trimesters: Potential for trans. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.